Moreover, the association between the BRAF and MEK inhibitor should be studied in a large cohort, as this treatment may have survival benefits in melanoma (72), and enrollment is currently ongoing for a study of de novo low-grade and relapsed or refractory high-grade gliomas (ClinicalTrials.gov Identifier: NCT02684058 and NCT02124772). The gene discussed is MAP2K7; the disease is central nervous system cancer.